DermaRite Industries recalled 6,973 cartridges of KleenFoam Antimicrobial Foam Soap on July 17, 2025. The product contains a harmful bacterial contamination, Burkholderia cepacia. Consumers should stop using the soap immediately and seek guidance from healthcare providers.
Microbial Contamination of Non-Sterile Drug Product: The products were found to be contaminated with the bacteria Burkholderia cepecia.
Consumers and healthcare providers should stop using this product immediately. Contact DermaRite Industries, LLC or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves KleenFoam Antimicrobial Foam Soap with Aloe Vera, 34 FL OZ (1000 mL) per cartridge. Lot numbers include 30705A, 30771A, 30920A, and several others with varying expiration dates from August 2025 to January 2027. The product was distributed nationwide in the USA.
KleenFoam soap has been found to be contaminated with Burkholderia cepacia, a bacterium that can pose serious health risks, especially to individuals with weakened immune systems or underlying health conditions. The contamination classifies this recall as Class I, indicating a high level of risk.
As of the recall date, there are no reported injuries associated with the contaminated soap. However, the potential health risks warrant immediate action.
Consumers should stop using the affected soap immediately and contact their healthcare provider for advice. DermaRite Industries will notify affected consumers by letter.
To report issues or seek further information, contact DermaRite Industries at 1-800-XXX-XXXX or visit their website.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.